Authors: Karp, CL van Boxel-Dezaire, AHH Byrnes, AA Nagelkerken, L

Citation: Cl. Karp et al., Interferon-beta in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10?, CURR OP NEU, 14(3), 2001, pp. 361-368

Authors: van Boxel-Dezaire, AHH Smits, M van Trigt-Hoff, SCJ Killestein, J van Houtwelingen, JC Polman, CH Nagelkerken, L

Citation: Ahh. Van Boxel-dezaire et al., Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis, J NEUROIMM, 120(1-2), 2001, pp. 152-160

Authors: van Boxel-Dezaire, AHH van Trigt-Hoff, SCJ Killestein, J Schrijver, HM van Houwelingen, JC Polman, CH Nagelkerken, L

Citation: Ahh. Van Boxel-dezaire et al., Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: Does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?, ANN NEUROL, 48(3), 2000, pp. 313-322

Authors: van Boxel-Dezaire, AHH Hoff, SCJ van Oosten, BW Verweij, CL Drager, AM Ader, HJ van Houwelingen, JC Barkhof, F Polman, CH Nagelkerken, L

Citation: Ahh. Van Boxel-dezaire et al., Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis, ANN NEUROL, 45(6), 1999, pp. 695-703